

**Nottinghamshire Leukaemia Appeal**  
**Financial Statements**  
**31 December 2024**

# **Nottinghamshire Leukaemia Appeal**

## **Financial Statements**

**Year ended 31 December 2024**

|                                               | <b>Page</b> |
|-----------------------------------------------|-------------|
| Trustees' annual report                       | <b>1</b>    |
| Independent examiner's report to the trustees | <b>4</b>    |
| Statement of financial activities             | <b>5</b>    |
| Statement of financial position               | <b>6</b>    |
| Notes to the financial statements             | <b>7</b>    |

# Nottinghamshire Leukaemia Appeal

## Trustees' Annual Report

**Year ended 31 December 2024**

The trustees present their report and the unaudited financial statements of the charity for the year ended 31 December 2024.

### Reference and administrative details

|                                    |                                                                              |
|------------------------------------|------------------------------------------------------------------------------|
| <b>Registered charity name</b>     | Nottinghamshire Leukaemia Appeal                                             |
| <b>Charity registration number</b> | 1155193                                                                      |
| <b>Principal office</b>            | Biodiscovery Institute-room B209<br>University Park<br>Nottingham<br>NG7 2RD |

### Trustees

Mr G K Abbott  
Mrs M S Stoakes  
Dr. M J Pallis

|                             |                 |
|-----------------------------|-----------------|
| <b>Independent examiner</b> | Mr K A Anderson |
|-----------------------------|-----------------|

### Governing Document

The Nottinghamshire Leukaemia Appeal also known as NLA is a charity which is an unincorporated trust governed by the Trust Deed dated 5<sup>th</sup> November 2013.

### Organisational Structure

Trustees meet quarterly with other members of the committee. Quarterly meetings are normally held to review fund raising activities being undertaken by supporters of the NLA and to consider applications for funding of research or patient welfare.

Trustees are selected on the basis of their experience and the benefits which they can bring to the charity. Other members are invited to join the committee based upon their knowledge and experience. The committee includes members who have relevant scientific medical knowledge required to assess research applications.

### Objectives and activities

The purposes of the charity are to promote the advancement of the treatment of leukaemia and blood cancers by supporting research at Nottingham University hospitals and to promote the treatment, care and welfare of patients with leukaemia and blood cancers at Nottingham University hospitals.

# Nottinghamshire Leukaemia Appeal

## Trustees' Annual Report

Year ended 31 December 2024

### Achievements and performance

#### Income

Income is generated from donations and promoting sponsored events.

The Trustees are very grateful to supporters of the charity in continuing to raise funds and to members of the public who have made donations.

#### Support

Nottingham University Department of Haematology has an established ethically approved bank of cells, DNA and RNA. The NLA provide £13,500 each year to make it possible to process samples from new patients, to separate and freeze their cells to make DNA and RNA and to keep alive stocks of blood cancer cell lines. This resource is essential for the success of research and has resulted in four peer-reviewed journal articles from the group in the past five years, with a further publication under review and others in preparation.

- Grundy M, Lucken K, Xing X, Simpson EL, Worker A, Bayyoomi A, Beckett AJ, Prior IA, Booth DG, Seedhouse CH. Abnormal nucleoli architecture and aggregate formation in nucleophosmin mutated acute myeloid leukaemia. Paper under review with Journal Cell Science
- James JR, Curd J, Ashworth JC, Abuhantash M, Grundy M, Seedhouse CH, Arkill KP, Wright AJ, Merry CLR, Thompson A. Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML. *Int J Mol Sci.* 2023;24(4):4235
- Bailey GD, Doolan L, Baskar A, Smith LC, Seedhouse CH. Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia. *Scientific Reports* 2020 10(1) 17695
- Grundy M, Al-Kaisi F, Cull J, Williams C, Smith D, Seedhouse CH. A same day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3 mimetic targeting in multiple myeloma cells. *EJHaem* 2020
- Alhuthali HM, Bradshaw TD, Lim KH, Tam KS, Seedhouse CH. The natural alkaloid Jerantinine B has activity in acute myeloid leukaemia cells through a mechanism involving c-Jun. *BMC Cancer* 2020 20(1) 629.

Funding for the salary of Dr Martin Grundy is in place until January 2026. Dr Grundy is in charge of collection and processing patient samples and has a wealth of experience in this technically challenging area (blood/bone marrow cells are incredibly fragile and notoriously difficult to work with to generate meaningful results). Research projects he is involved in include testing new genetic agents in leukaemia and assessing exactly what occurs in leukaemia cells as they proliferate and how this differs to normal healthy blood cells. He has also been involved in developing models for leukaemia and myeloma to best replicate what happens in a patient. In addition, Dr Grundy is working on the role of the mutated nucleophosmin protein in leukaemia and has been using special imaging equipment to study what happens in real time in leukaemia cells as they grow and divide. He has found abnormalities in leukaemia cells harbouring the mutated protein. These results have been submitted for publication in the *Journal of Cell Science* and the manuscript is currently under expert review. The work is continuing to identify how we might specifically target and kill the mutant cells without affecting the normal blood cells.

The NLA are also funding Dr Alexander Kondrashov for five months. Dr Kondrashov is developing novel genetic models to recreate leukaemia initiating events. This involves growing leukaemia cells from patients in special culture to allow the production and manipulations of stem cell – these are the cells that start the leukaemia. The aim is to develop a novel model of early onset leukaemia.

The work supported fulfils the objective of the NLA to promote the advancement of research into the treatment of leukaemia in Nottinghamshire. The quality of the funded research is evident by publication in international peer-reviewed journals (three articles published in 2018, one in 2019, three in 2020, one in 2023, one under review 2024 and several others in preparation).

# **Nottinghamshire Leukaemia Appeal**

## **Trustees' Annual Report**

### **Year ended 31 December 2024**

Research updates and outputs are regularly featured on the NLA website to ensure our supporters are aware of the research work being funded.

#### **Financial review**

Donations and legacies received were £3,624 (2023: £4,048).

Fund raising events generated net income of £35,675 (2023: £42,675).

Running costs were kept to a minimum at £710 (2023: £988).

No payments (2023: Nil) or other benefits were made to trustees and committee members.

Awards and donations made were £60,548 (2023: £123,972).

Unrestricted reserves were £42,810 (2023: £63,574).

The trustees' annual report was approved on 1<sup>st</sup> September 2025 signed on behalf of the board of trustees by:

Mr G K Abbott  
Trustee

# **Nottinghamshire Leukaemia Appeal**

## **Independent Examiner's Report to the Trustees of Nottinghamshire Leukaemia Appeal**

**Year ended 31 December 2024**

I report to the trustees on my examination of the financial statements of Nottinghamshire Leukaemia Appeal ('the charity') for the year ended 31 December 2024.

### **Responsibilities and basis of report**

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

### **Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the financial statements do not accord with those records;
3. the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Mr K A Anderson

Independent Examiner

22 September 2025

# Nottinghamshire Leukaemia Appeal

## Statement of Financial Activities

Year ended 31 December 2024

|                                      |      | 2024               |                 | 2023            |
|--------------------------------------|------|--------------------|-----------------|-----------------|
|                                      |      | Unrestricted funds | Total funds     | Total funds     |
|                                      | Note | £                  | £               | £               |
| <b>Incoming Resources</b>            |      |                    |                 |                 |
| <b>Income and endowments</b>         |      |                    |                 |                 |
| Donations and legacies               | 4    | 3,624              | 3,624           | 4,048           |
| Funding raising activities           | 5    | 35,917             | 35,917          | 44,375          |
| Investment income                    | 6    | 2,653              | 2,653           | 1,664           |
| <b>Total income</b>                  |      | <u>42,194</u>      | <u>42,194</u>   | <u>50,087</u>   |
|                                      |      | =====              | =====           | =====           |
| <b>Resources Expended</b>            |      |                    |                 |                 |
| <b>Costs</b>                         |      |                    |                 |                 |
| Costs of fund-raising activities     | 7    | 1,700              | 1,700           | 1,700           |
| Charitable donations and other costs | 8,9  | 61,258             | 61,258          | 124,960         |
| <b>Total Outgoings</b>               |      | <u>62,958</u>      | <u>62,958</u>   | <u>126,660</u>  |
|                                      |      | =====              | =====           | =====           |
| <b>Net (deficit)</b>                 |      | <u>(20,764)</u>    | <u>(20,764)</u> | <u>(76,573)</u> |
|                                      |      | =====              | =====           | =====           |
| <b>Reconciliation of funds</b>       |      |                    |                 |                 |
| Total funds brought forward          |      | 63,574             | 63,574          | 140,417         |
| <b>Total funds carried forward</b>   |      | <u>42,810</u>      | <u>42,810</u>   | <u>63,574</u>   |
|                                      |      | =====              | =====           | =====           |

The statement of financial activities includes all gains and losses recognised in the year.  
All income and expenditure is derive from continuing activities.

# Nottinghamshire Leukaemia Appeal

## Statement of Financial Position

31 December 2024

|                                                       | Note | 2024<br>£      | 2023<br>£      |
|-------------------------------------------------------|------|----------------|----------------|
| <b>Current Assets</b>                                 |      |                |                |
| Cash at bank and in hand                              |      | 222,736        | 221,922        |
| <b>Total current assets</b>                           |      | <u>222,736</u> | <u>221,922</u> |
| <b>Creditors: amounts falling due within one year</b> | 10   | 139,737        | 82,366         |
| <b>Net Current Assets</b>                             |      | <u>82,999</u>  | <u>139,556</u> |
| <b>Creditors: amounts falling due after one year</b>  | 10   | 40,189         | 75,982         |
| <b>Total Net Assets</b>                               |      | <u>42,810</u>  | <u>63,574</u>  |
| <b>Funds of the charity</b>                           |      |                |                |
| Unrestricted funds                                    |      | 42,810         | 63,574         |
| <b>Total charity funds</b>                            |      | <u>42,810</u>  | <u>63,574</u>  |

These financial statements were approved by the board of trustees and authorised for issue on  
and are signed on behalf of the board of trustees by:

Mr G K Abbott  
Trustee

# Nottinghamshire Leukaemia Appeal

## Notes to the Financial Statements *(continued)*

### Year ended 31 December 2024

#### 1. General information

The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the principal office is Biodiscovery Institute-room B209 University Park, Nottingham, NG7 2RD.

#### 2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Charities Act 2011.

#### 3. Accounting policies

##### Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure.

The financial statements are prepared in sterling, which is the functional currency of the entity.

##### Going concern

There are no material uncertainties about the charity's ability to continue.

##### Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

##### Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:

- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably.
- legacy income is recognised when receipt is probable and entitlement is established.

##### Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:

- expenditure on raising funds includes the costs of all fundraising activities, events, non-charitable trading activities, and the sale of donated goods.
- expenditure on charitable activities includes all costs incurred by a charity in undertaking

# Nottinghamshire Leukaemia Appeal

## Notes to the Financial Statements *(continued)*

### Year ended 31 December 2024

activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities.

- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

#### 4. Donations and legacies

|                        | <b>Total Funds<br/>2024<br/>£</b> | <b>Total Funds<br/>2023<br/>£</b> |
|------------------------|-----------------------------------|-----------------------------------|
| <b>Donations</b>       |                                   |                                   |
| Donations and Legacies | 3,624                             | 4,048                             |
|                        | =====                             | =====                             |

#### 5. Fund raising activities

|                        | <b>Total Funds<br/>2024<br/>£</b> | <b>Total Funds<br/>2023<br/>£</b> |
|------------------------|-----------------------------------|-----------------------------------|
| Fundraising activities | 35,917                            | 44,375                            |
|                        | =====                             | =====                             |

#### 6. Investment income

|                          | <b>Total Funds<br/>2024<br/>£</b> | <b>Total Funds<br/>2023<br/>£</b> |
|--------------------------|-----------------------------------|-----------------------------------|
| Bank interest receivable | 2,653                             | 1,664                             |
|                          | =====                             | =====                             |

#### 7. Costs of fundraising activities

|                    | <b>Total Funds<br/>2024<br/>£</b> | <b>Total Funds<br/>2023<br/>£</b> |
|--------------------|-----------------------------------|-----------------------------------|
| Fund raising costs | 1,700                             | 1,700                             |
|                    | =====                             | =====                             |

#### 8. Expenditure on charitable activities

|                                  | <b>Total Funds<br/>2024<br/>£</b> | <b>Total Funds<br/>2023<br/>£</b> |
|----------------------------------|-----------------------------------|-----------------------------------|
| Charity donations and support    | 60,548                            | 113,972                           |
| Administration and support costs | 710                               | 988                               |
|                                  | 61,258                            | 114,960                           |
|                                  | =====                             | =====                             |

# **Nottinghamshire Leukaemia Appeal**

## **Notes to the Financial Statements** *(continued)*

**Year ended 31 December 2024**

### **9. Trustee remuneration and expenses**

No remuneration or other benefits were received by the trustees.

### **10. Creditors**

Creditors include committed support on 31 December 2024 of £179,928 (2023: £156,648) of which £40,189 (2023: £75,982) is due after more than one year.

